Wedbush Equities Analysts Boost Earnings Estimates for RARE

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Research analysts at Wedbush upped their FY2027 earnings per share (EPS) estimates for shares of Ultragenyx Pharmaceutical in a note issued to investors on Thursday, January 23rd. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will post earnings per share of $1.05 for the year, up from their prior forecast of $1.04. Wedbush has a "Neutral" rating and a $48.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($6.14) per share. Wedbush also issued estimates for Ultragenyx Pharmaceutical's FY2028 earnings at $1.92 EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping analysts' consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The firm had revenue of $139.49 million during the quarter, compared to the consensus estimate of $135.28 million. The firm's revenue for the quarter was up 42.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.23) earnings per share.

Other analysts have also issued research reports about the company. Wells Fargo & Company lifted their price objective on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an "overweight" rating in a report on Friday, December 20th. Piper Sandler raised their price objective on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an "overweight" rating in a report on Monday, January 13th. HC Wainwright reaffirmed a "buy" rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, December 24th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Wednesday. Finally, JPMorgan Chase & Co. cut their target price on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an "overweight" rating for the company in a research note on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, Ultragenyx Pharmaceutical presently has an average rating of "Moderate Buy" and a consensus price target of $92.43.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE stock traded down $0.79 on Friday, hitting $44.06. The company's stock had a trading volume of 455,859 shares, compared to its average volume of 1,149,744. Ultragenyx Pharmaceutical has a fifty-two week low of $37.02 and a fifty-two week high of $60.37. The firm's fifty day moving average price is $44.63 and its 200-day moving average price is $49.59. The stock has a market capitalization of $4.07 billion, a price-to-earnings ratio of -6.87 and a beta of 0.58.

Insider Activity at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 11,727 shares of the company's stock in a transaction on Monday, December 30th. The shares were sold at an average price of $42.23, for a total transaction of $495,231.21. Following the completion of the sale, the chief executive officer now directly owns 2,183,985 shares in the company, valued at $92,229,686.55. This represents a 0.53 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 5.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several hedge funds and other institutional investors have recently modified their holdings of RARE. True Wealth Design LLC bought a new position in Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $43,000. Values First Advisors Inc. bought a new stake in Ultragenyx Pharmaceutical in the third quarter valued at $56,000. Wilmington Savings Fund Society FSB purchased a new position in Ultragenyx Pharmaceutical during the 3rd quarter valued at $83,000. Nomura Asset Management Co. Ltd. purchased a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter worth about $93,000. Finally, R Squared Ltd bought a new stake in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at about $103,000. 97.67% of the stock is owned by institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.